Bradsaúde (SAUD3) announced on Tuesday, November 10, 2026, that Atlântica Hospitais e Participações, its indirect subsidiary focused on hospital investments, entered into a binding memorandum of understanding with Fleury. The agreement sets out the main terms for investing in a new outpatient oncology company, FleuryOnco, with a planned investment of R$ 72 mi in the initial phase. Ownership will be 50.1% Fleury and 49.9% Atlântica.
FleuryOnco will operate in outpatient oncology care, offering oncology therapies, care and multidisciplinary services supporting treatment, and clinical research activities in oncology and related areas. Medical, operational and commercial management will be Fleury's responsibility.
The company will operate under two brands: Fleury Oncologia, focused on São Paulo, and Onco One, with nationwide operations. As the first stage of the expansion plan, the opening of seven units is planned by the end of 2027.
According to Bradsaúde, the transaction is aligned with Atlântica's strategy of investing across the healthcare value chain through partnerships with leading operators. Closing depends on the signing of definitive agreements and the fulfillment of customary conditions precedent, including regulatory approvals.
